ALAndreas Lutterotti

Andreas Lutterotti

*This is an algorithmically generated author record based on publicly available information.

Andreas Lutterotti has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Kupffer cells are key mediators of antigen-specific immune tolerance by peptide-coupled red blood cells

    by Vasileia Kalaitzaki, Pietro Oldrati, Filipa M. Ferreira, Antonios Katsoulas, Ahmed Ali, Livio Baselgia, Yun Liu, Jincheng Fang, Roman Sankowski, Mai Matsushita, et al.

    Induction of antigen-specific immune tolerance is the most precise method for reverting an autoreactive immune response in diseases such as multiple sclerosis (MS). Coupling red blood cells (RBCs) with a cocktail of MS immunodominant peptides is a promising approach to induce antigen-specific immune tolerance in patients. Here, we show that RBCs coupled with disease-inducing antigen efficiently prevent the development of experimental autoimmune encephalomyelitis, when administered prophylactically, and ameliorate disease symptoms when given therapeutically. The tolerogenic activity of peptide-coupled RBCs (pcRBC) was antigen specific and dependent on both cell and peptide dose. Kupffer cells (KC) were the primary phagocytes of pcRBC, and their uptake of pcRBC did not require complement component 3, SIRPα, and Stabilin 1 and 2. KC were indispensable for the induction of tolerance, which was accompanied by programmed death-ligand 1 up-regulation and a tolerogenic transcriptional shift. Our findings establish KC as central mediators of pcRBC-induced immune tolerance and provide mechanistic insight for the use of this therapeutic strategy in autoimmune disease.

  • Open Access

    Treatment of multiple sclerosis with peptide-coupled red blood cells induces antigen-specific T regulatory cells

    by Andreas Lutterotti, Thomas Ludersdorfer, María José Docampo, Muriel Morax, Helen Hayward-Koennecke, Pietro Oldrati, Vasileia Kalaitzaki, Zoe Marti, Angela Zaugg, Mattias Bronge, et al.

    Inducing antigen-specific immune tolerance is a long-standing aim in organ-specific autoimmune diseases including multiple sclerosis (MS). We developed a therapy based on autologous red blood cells (RBCs) as tolerizing carriers of autoantigens and tested these in an open-label, dose-escalation, phase Ib clinical trial with clinical, imaging, and mechanistic readouts. RBCs coupled with seven immunodominant myelin peptides (pcRBCs) were safe and well tolerated. Several clinical and imaging readouts remained stable, which was supported by a reduction of neurofilament light chain indicating reduced tissue inflammation in the brain. Single-cell RNA sequencing identified expansion of antigen-specific CD4+ memory T cells with regulatory phenotypes and loss of proinflammatory cells three months after a single administration of pcRBCs. This was corroborated by a reduction of autoreactive CD4+ T cell responses and an early increase of IL-10, Tr1 regulatory T cells and tolerogenic monocytes and plasmacytoid dendritic cells. Biodistribution studies in mice and humans demonstrate that pcRBCs are rapidly processed by Kupffer cells in the liver and by marginal zone macrophages in the spleen. In summary, pcRBCs are a promising autologous cell therapy for achieving antigen-specific immune tolerance in MS.


  • Open Access

    Figure S3 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma

    by Jian Wang, Tobias Weiss, Marian C. Neidert, Nora C. Toussaint, Reza Naghavian, Carla Sellés Moreno, Magdalena Foege, Paula Tomas Ojer, Gioele Medici, Ivan Jelcic, et al.

    Peripheral blood T cell responses to v-peptides increase with repetitive vaccination. (A) PBMCs were collected 3 weeks after the 2nd peptide cocktail vaccination, and CD45RA-negative PBMCs were stimulated with 4 μg/mL Tetanus toxoid, 2 μM CEF II peptide pool or 5 μM v-peptides for 7 days. 5-10 replicate wells were tested for proliferation, and proliferation measured by 3H-thymidine incorporation assay. CD45RA-negative PBMCs collected before vaccination were used as reference. The proliferation strength is depicted as stimulation index (SI). The red dotted line indicates a stimulatory response of SI = 2, and values above the red dotted line were considered positive. (#) indicates the peptide that was used in the vaccinations. (B) PBMCs were collected 5 weeks after the 3rd peptide cocktail vaccination, and CD45RA-negative PBMCs were stimulated with 4 μg/mL Tetanus toxoid, 2 μM CEF II peptide pool or 5 μM v-peptides for 7 days. 5-10 replicate wells were tested for proliferation, and proliferation was measured by 3H-thymidine incorporation assay. CD45RA-negative PBMCs collected before vaccination were used as the control. Data are expressed as mean ± SEM, and p values were determined using an unpaired t-test. * p < 0.05, ** p < 0.01, *** p < 0.001.

  • Open Access

    Figure S5 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma

    by Jian Wang, Tobias Weiss, Marian C. Neidert, Nora C. Toussaint, Reza Naghavian, Carla Sellés Moreno, Magdalena Foege, Paula Tomas Ojer, Gioele Medici, Ivan Jelcic, et al.

    Activated T lymphocytes in recurrent tumor interact with macrophages. (A) Expression of T cell activating markers HLA-DR and Tim-3 in the perivascular areas and peritumoral areas of the primary and recurrent tumor was detected by IMC. (B) CD3-CD7+ NK cells infiltrated in the perivascular areas and peritumoral areas of the primary and recurrent tumor was detected by IMC. (C) Pro-inflammatory CD11c+ CD68+ macrophages, which had infiltrated the perivascular areas and peritumoral areas of the primary and recurrent tumor, were detected by IMC. (D) Colocalization analysis of CD68+ macrophages and CD3+ T cells in the perivascular areas and peritumoral areas of the primary and recurrent tumor were detected by IMC. Scale bars are indicated in the figures.

  • Open Access

    Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma

    by Jian Wang, Tobias Weiss, Marian C. Neidert, Nora C. Toussaint, Reza Naghavian, Carla Sellés Moreno, Magdalena Foege, Paula Tomas Ojer, Gioele Medici, Ivan Jelcic, et al.

    Predicted TSA/TAA-derived N-peptides and D-neopeptides

  • Open Access

    Figure S6 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma

    by Jian Wang, Tobias Weiss, Marian C. Neidert, Nora C. Toussaint, Reza Naghavian, Carla Sellés Moreno, Magdalena Foege, Paula Tomas Ojer, Gioele Medici, Ivan Jelcic, et al.

    TILs do not respond to N-class I-peptides. TILs were stimulated with 5- or 10 μM N-class I-peptides for 5 days. 5 replicate wells were tested for proliferation, and proliferation was measured by 3H-thymidine incorporation assay. The proliferation strength is depicted as SI. (#) indicates the peptide that was used in the 1st to 4th vaccinations. Data are expressed as mean ± SEM.

  • Open Access

    Figure S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma

    by Jian Wang, Tobias Weiss, Marian C. Neidert, Nora C. Toussaint, Reza Naghavian, Carla Sellés Moreno, Magdalena Foege, Paula Tomas Ojer, Gioele Medici, Ivan Jelcic, et al.

    PBMCs collected before vaccination show low/no response to candidate vaccine peptides. (A) The nomenclature of the N-peptides and D-neopeptides. I or II indicate if the peptides were chosen/designed for HLA class I or -II binding; MUT/RNA/GBM indicates a naturally mutated peptide (MUT), derivation from the over-/highly expressed genes (RNA) or from known glioblastoma (GBM) targets; X indicates the number of the peptide; 0 or 1 indicate if the peptides had been artificially mutated (1) or not (0); (’) indicates that peptides contained the naturally mutated amino acid. (B) PBMCs collected before vaccination were stimulated with 4 μg/mL Tetanus toxoid or 2 μM CEF II peptide pool for 7 days, and proliferation was measured by ³H-thymidine incorporation assay. The proliferation strength is depicted as counts per minute (cpm). In each group, the N-peptides and their corresponding D-neopeptides are included, and the designed mutated positions are highlighted in the red box. The blue dotted line indicates the mean value of the no peptide control. The red dotted line indicates the mean value plus three standard deviations of the no peptide control. Values above the red dotted line were considered positive. (C) PBMCs collected before vaccination were stimulated with 5 μM predicted class I-peptides, including N-peptides and D-neopeptides, for 7 days, and proliferation was measured by ³H-thymidine incorporation assay. 10-15 replicate wells were tested for proliferation, and responses were depicted as cpm. (D) PBMCs collected before vaccination were stimulated with 5 μM predicted class II-peptides, including N-peptides and D-neopeptides, for 7 days, and proliferation was measured by ³H-thymidine incorporation assay. 10-15 replicate wells were tested for proliferation, and responses were depicted as cpm.

  • Open Access

    Figure S7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma

    by Jian Wang, Tobias Weiss, Marian C. Neidert, Nora C. Toussaint, Reza Naghavian, Carla Sellés Moreno, Magdalena Foege, Paula Tomas Ojer, Gioele Medici, Ivan Jelcic, et al.

    Designed mutations increase the stimulatory strength of D-neopeptides above N-peptides. (A) TILs were stimulated with 5 μM class I-peptides, including N-peptides and D-neopeptides, for 5 days. 5 replicate wells were tested for proliferation, and proliferation was measured by 3H-thymidine incorporation assay. In each group, the N-peptides and their corresponding D-neopeptides are included, and the designed mutated positions are highlighted in the red box. The blue dotted line indicates the mean value of the no peptide control. The red dotted line indicates the mean value plus three standard deviations of the no peptide control. Values above the red dotted line were considered positive. (#) indicates the peptide that was used in the 1st to 4th vaccinations. (B) TILs were stimulated with 5 μM class II-peptides, including N-peptides and D-neopeptides, for 5 days. 5 replicate wells were tested for proliferation, and proliferation was measured by 3H-thymidine incorporation assay.

  • Open Access

    Figure S1 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma

    by Jian Wang, Tobias Weiss, Marian C. Neidert, Nora C. Toussaint, Reza Naghavian, Carla Sellés Moreno, Magdalena Foege, Paula Tomas Ojer, Gioele Medici, Ivan Jelcic, et al.

    Schematic outline of the personalized peptide vaccination. (A) Timeline of clinical events for a patient with glioblastoma in whom we applied a highly personalized peptide vaccination. I. Vaccine peptide design. Surgically resected primary glioblastoma and PBMCs were collected. Somatic mutants and over-/highly expressed genes in glioblastoma were identified as TSAs and TAAs by WES and RNA-seq, and the HLA genotype were identified with PBMCs by DNA sequencing. Potential vaccine peptides were predicted and selected from TSAs and TAAs based on HLA binding prediction. Peptide cocktails containing ~25 peptides for HLA class I or II molecules were prepared for vaccination. II. Peptide cocktail vaccination and testing. The patient was s.c. vaccinated with the peptide cocktails, and Imiquimod or XS15 + MontanideTM were used as the adjuvant. Meanwhile, the patient received treatment with pembrolizumab and bevacizumab. No dexamethasone was given throughout the periods of vaccination. PBMCs were collected after vaccination at the indicated time points and tested with vaccine peptides to examine the effect of immunotherapy. Surgically resected recurrent glioblastoma was collected after four vaccinations, and tumor-infiltrating lymphocytes (TILs) were isolated and tested with vaccine peptides. (B) HLA genotypes of the patient with glioblastoma, including HLA-A, HLA-B, HLA-DR, HLA-DP, and HLA-DQ alleles. n.a. indicates not available.